OrbiMed’s AUXILIUM PHARAMCEUTICALS INC AUXL Stock Holding History

OrbiMed’s Portfolio AUXL Stock Details AUXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-60,000	Closed	-$998K	–	144
2013 Q2	$998K	Buy	+60,000	New	+$958K	0.02%	122

Other funds holding AUXL

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed's AUXL Position: Q3 2013 in Review

OrbiMed sold out of AUXILIUM PHARAMCEUTICALS INC (AUXL) in Q3 2013, closing a stake of 60,000 shares — an estimated $998K sold.

OrbiMed first reported a position in AUXL in Q2 2013 and held it in 1 quarter. The position peaked at $998K in Q2 2013. 150 funds tracked by Wall St. Rank hold AUXL as of Q3 2013.

OrbiMed reported no remaining AUXILIUM PHARAMCEUTICALS INC position as of Q3 2013 after selling out during the quarter.
OrbiMed sold 60,000 AUXILIUM PHARAMCEUTICALS INC shares in Q3 2013, an estimated $998K.
OrbiMed first reported a position in AUXILIUM PHARAMCEUTICALS INC in Q2 2013 and held it in 1 quarter.
OrbiMed's AUXILIUM PHARAMCEUTICALS INC position peaked at $998K in Q2 2013.
150 funds tracked by Wall St. Rank held AUXILIUM PHARAMCEUTICALS INC as of Q3 2013.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.